Recently Featured

IDBS and Alchemi Partner to Streamline AI-Driven Biopharma Regulatory Filings

June 23, 2026
IDBS, a provider of cloud software for the biopharma sector, has announced a partnership with Alchemi, an applied AI company, to enhance the efficiency of regulatory filings through AI integration. This collaboration aims to connect AI agents to data captured within the IDBS Polar platform, which serves as a governed backbone for data throughout the…

Biogen adds more immune drugs in $1B buyout of secretive startup RayThera

June 23, 2026
Biogen has announced a significant acquisition, purchasing the startup RayThera for $1 billion, a move that underscores its strategic focus on expanding its portfolio in the immune drug sector. While the specific drugs involved in the transaction have not been disclosed, the patents secured by RayThera hint at potential therapeutic innovations that could enhance Biogen’s…

FTC Orders Aurobindo to Divest Four Drugs to Complete $250M Lannett Acquisition

June 23, 2026
The Federal Trade Commission (FTC) has mandated that Aurobindo Pharma divest four specific drugs as a condition for finalizing its $250 million acquisition of Lannett Company, a Pennsylvania-based generics specialist. This decision stems from concerns regarding potential anticompetitive effects that could arise from the merger, which is significant given the current landscape of the pharmaceutical…

Pfizer CFO to step down; Denali sells a regulatory fast-pass

June 23, 2026
Pfizer’s Chief Financial Officer, Dave Denton, is set to leave the company as he transitions to a role outside the pharmaceutical sector. This leadership change comes at a critical time for Pfizer, which is navigating a complex landscape of patent expirations and competitive pressures in the biopharmaceutical market. The company now faces the challenge of…

Ongoing Cases